Thermo Fisher Scientific Inc. (TMO) is under the radar with several notable headlines. A fair value analysis suggests that it is 31% undervalued, sparking interest from various entities. Border to Coast Pensions Partnership Ltd and Foresight Group Ltd Liability Partnership have increased their stake in TMO, among others. In turn, TMO continues to outperform the market. The firm is slated to present updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. Speculations of TMO being a viable, safe dividend stock for 2025 gain momentum while TMO announces to hold its earnings conference call on January 30, 2025. Receiving its fair share of skepticism, Morgan Stanley issues a pessimistic forecast for TMO's stock price while others boost holdings. TMO has been pioneering in nanotechnology and its Olink platform has been chosen for the world's largest human proteome study. The firm has also completed a $1B share repurchase and plans to launch a $4B share buyback program. Despite the insiders disposing stock, TMO's financial outlook remains promising.
Thermo Fisher Scientific TMO News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 18 Jan 2025 15:07:27 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 2
